- Home
- BTDR vs NVAX Comparison
BTDR vs NVAX Comparison
Compare BTDR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTDR
- NVAX
- Stock Information
- Founded
- BTDR 2021
- NVAX 1987
- Country
- BTDR Singapore
- NVAX United States
- Employees
- BTDR N/A
- NVAX N/A
- Industry
- BTDR EDP Services
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTDR Technology
- NVAX Health Care
- Exchange
- BTDR Nasdaq
- NVAX Nasdaq
- Market Cap
- BTDR 1.9B
- NVAX 2.0B
- IPO Year
- BTDR N/A
- NVAX 1995
- Fundamental
- Price
- BTDR $20.49
- NVAX $8.70
- Analyst Decision
- BTDR Strong Buy
- NVAX Buy
- Analyst Count
- BTDR 10
- NVAX 6
- Target Price
- BTDR $19.30
- NVAX $17.83
- AVG Volume (30 Days)
- BTDR 11.2M
- NVAX 3.6M
- Earning Date
- BTDR 11-18-2024
- NVAX 11-12-2024
- Dividend Yield
- BTDR N/A
- NVAX N/A
- EPS Growth
- BTDR N/A
- NVAX N/A
- EPS
- BTDR N/A
- NVAX N/A
- Revenue
- BTDR $395,612,000.00
- NVAX $885,193,000.00
- Revenue This Year
- BTDR N/A
- NVAX N/A
- Revenue Next Year
- BTDR $55.30
- NVAX N/A
- P/E Ratio
- BTDR N/A
- NVAX N/A
- Revenue Growth
- BTDR 19.58
- NVAX N/A
- 52 Week Low
- BTDR $5.23
- NVAX $3.53
- 52 Week High
- BTDR $25.51
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- BTDR 61.74
- NVAX 46.62
- Support Level
- BTDR $18.42
- NVAX $8.50
- Resistance Level
- BTDR $25.51
- NVAX $9.75
- Average True Range (ATR)
- BTDR 3.34
- NVAX 0.50
- MACD
- BTDR -0.12
- NVAX 0.06
- Stochastic Oscillator
- BTDR 59.45
- NVAX 35.19
About BTDR Bitdeer Technologies Group
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.